Sun Pharmaceutical Industries entered its landmark $11.75 billion acquisition of Organon & Co. with a net cash position of approximately $3.2 billion, providing critical flexibility in funding structure. The company deployed $2-2.5 billion of existing cash reserves while securing committed bank financing of $9.25-9.75 billion, demonstrating how internal accruals reduce absolute debt requirements. This approach contrasts sharply with the 2005-10 acquisition wave when Indian companies relied heavily on leverage. Transcripts +1
The financial discipline is evident in the pro forma metrics. The combined Sun Pharma-Organon entity targets a net debt-to-EBITDA ratio of 2.3 times, supported by annual free cash flow generation of nearly $2.5 billion. This conservative leverage profile stands in stark contrast to the 4-6x leverage ratios common during the mid-2000s expansion cycle, when companies like Tata Steel paid 608 pence per share for Corus—34% above initial offers—creating significant financial pressure. InvestorPresentations
This deleveraging trend across Corporate India has been building for years. Companies have been using rising profits to repay debt, with capacity utilisation above 75% yet investment intentions moderating. The result: stronger balance sheets that can support strategic expansion without excessive leverage. When outbound transactions accounted for 84% of India's total M&A value in the April-June 2026 quarter, reaching $23.44 billion, it wasn't despite conservative financial management—it was because of it.
The fundamental shift in acquisition strategy is perhaps best illustrated by comparing Sun Pharma's current approach with the scale-driven deals of the past. Tata Steel's 2007 acquisition of Corus for $12.1 billion aimed to become the world's fifth-largest steel producer. Hindalco's $6 billion Novelis purchase in 2007 sought vertical integration to become the largest aluminum rolled products company. Tata Motors' $2.3 billion Jaguar Land Rover deal in 2008 targeted luxury automotive brands and global distribution networks.
These were transformational acquisitions designed to establish global presence through sheer scale. The current generation of deals is fundamentally different. Sun Pharma's Organon acquisition focuses on specialty medicines, biosimilars platform entry, and women's health capabilities. The deal increases innovative medicines revenue share from 20% to 27%, positioning Sun Pharma among the top 25 global pharmaceutical companies with top 3 positioning in women's health and 7th largest global biosimilar player. Others +1
Similarly, Bharti Airtel Limited's $2.97 billion stake increase in Airtel Africa demonstrates market access prioritization over pure geographic expansion. The strategy focuses on deepening presence in existing high-growth markets rather than entering new territories. Management emphasized that Airtel Africa is the "Group's pre-eminent growth engine," with the transaction being immediately accretive to EPS. Others
Indian companies are increasingly targeting capabilities that cannot be developed organically within reasonable timeframes. In technology, the focus has shifted from acquiring AI models to acquiring the infrastructure that powers autonomous agents. Global AI M&A reached record levels in 2025, with 266 deals closing in Q1 2026—a 90% year-over-year increase. Indian IT companies are pursuing AI and cloud capabilities through acquisitions, with technology M&A in India reaching $27.5 billion in 2025, a 30% increase over 2024.
The rationale is straightforward: building comparable AI capabilities from scratch costs more and takes longer than acquiring them. Enterprise software companies have realized that customers expect AI-native functionality, and acquisition is the fastest path to delivery. This is particularly relevant for Indian IT services companies that need to embed AI-driven tools into core processes including data analytics, automation, and customer engagement.
In pharmaceuticals, the capability acquisition focus is equally pronounced. Beyond Sun Pharma's move into women's health and biosimilars, Indian companies are targeting complex generics, specialty formulations, and differentiated drug-delivery platforms. The Indian pharmaceutical market is projected to reach $80 billion by 2031, with profit pools shifting toward higher technical barriers and fewer qualified competitors.
Global valuation corrections across technology, healthcare, industrial, and consumer sectors have created attractive acquisition opportunities for Indian companies. Technology M&A aimed at acquiring AI capabilities has cooled from 2025 levels, with sector valuations re-rated lower. Software M&A volumes declined in early 2026 as buyers reassess AI-related disruption.
Meanwhile, Indian equity markets command premium valuations, providing efficient capital raising for overseas acquisitions. The Nifty 50 P/E ratio expanded from 21.79 in December 2024 to 22.75 in December 2025, with the market delivering approximately 12% total shareholder return. This premium valuation environment allows Indian companies to raise capital at attractive multiples and deploy it in markets where valuations are more reasonable.
The impact is visible in deal patterns. India recorded 162 outbound M&As worth $18.2 billion in 2025, with 56 acquisitions valued at $3.9 billion in Q1 CY2026. While deal volume moderated, the strategic focus intensified. The average deal size increased from $112 million in 2025 to $70 million in Q1 2026, reflecting greater selectivity and targeted capability acquisition rather than broad-based expansion.
India's Overseas Investment Rules, Regulations and Directions introduced in 2022 have provided greater clarity and structure to outbound investments. The new framework replaced nearly two decades of previous regulations with a unified three-part structure covering Rules, Regulations, and Directions. Key improvements include clearer definitions of investment types, liberalized investment limits up to 400% of net worth under the Automatic Route, and enhanced flexibility in deal structuring including deferred payments and multiple funding modes.
This regulatory clarity has been accompanied by increased emphasis on compliance. Indian companies must navigate complex sanctions regimes, export control requirements, and multi-jurisdictional regulatory approvals. The extraterritorial application of US sanctions means Indian companies conducting dollar-denominated transactions come under US authorities' purview regardless of transaction origin. This has necessitated sophisticated compliance frameworks, including automated screening software and transaction monitoring systems.
Transaction structures have evolved accordingly. Governance rights, tax structuring, and intellectual property ownership considerations now play central roles in deal design. The Income Tax Act 2025 has introduced changes affecting M&A tax structuring, including a unified "Tax Year" replacing the dual concepts of Assessment Year and Previous Year, reducing confusion around timing and simplifying tax analysis for deferred closings, escrows, and earn-outs.
The integration challenges facing Sun Pharma in combining operations with Organon across more than 140 markets illustrate the complexity of modern capability-led acquisitions. The company has established a dedicated Integration Management Office and initiated day-one preparedness activities. Management has identified cross-cultural assimilation as "extremely important," with integration planning specifically including alignment of "ways of working" between the organizations. Transcripts +2
These challenges differ significantly from scale-driven acquisitions like Tata Steel's Corus deal. The Corus acquisition suffered from cultural integration failures, lack of post-acquisition control, and insufficient knowledge transfer. Tata paid far more than Corus was worth, with the total settlement reaching $12 billion including $6 billion in debt. The energy cost structure in the UK, with environmental policies and green taxes substantially increasing costs for heavy manufacturing, created additional operational burdens.
Current capability-led acquisitions face different risks. The primary concerns are talent retention, business continuity during transition, and realization of projected synergies. Sun Pharma management acknowledged risks related to diverting management attention from ongoing operations and the impact on Organon's ability to maintain relationships with customers, suppliers, and business partners. Others
The evidence suggests this is a structural rather than cyclical trend in India Inc's global expansion. Outbound M&A is increasingly becoming a strategic extension of Corporate India's growth agenda. Three decades after economic liberalization, India's place in the global economy is changing. If the first generation of overseas acquisitions helped Indian companies establish a global presence, the current wave is about sharpening their competitive edge.
The increase in outbound transactions' share of total M&A deal volume from 12.4% in H1 2024 to 17.6% in H1 2026 reflects this structural evolution. Rather than chasing size alone, companies are using acquisitions to strengthen their ability to compete across markets, technologies, and business cycles. Stronger balance sheets, easier access to capital, growing global ambitions, and the need to operate closer to customers are likely to keep Indian companies looking overseas, even as financing costs, geopolitical uncertainty, and execution risks continue to influence dealmaking.
This strategic evolution—from scale-driven to capability-led acquisitions—represents a fundamental maturation of India Inc's global expansion strategy. The emphasis on financial discipline, strategic fit, and sophisticated integration approaches will likely define the next phase of India Inc's global journey, building sustainable competitive advantages rather than pursuing scale for its own sake.
